60 speakers featured at BIO-Europe Spring 2010 March 8-10 in Barcelona
Exponential growth is the strongest indicator of success for any start-up venture, and BIO-Europe Spring is experiencing a powerful lift as it reaches its fourth year. Registrations for the event began as early as November and continued in a steady stream approaching a record 1,735 delegates from 1038 companies in 42 countries.
The extraordinary number of partnering meetings, powered by the industry’s leading technology platform partneringONE®, explains in part the surging popularity of BIO-Europe Spring.
The other leading attraction for the event is a conference program that dominates activities on the first day and brings together more than 60 leading executives in Life Sciences for intensive panel discussions and workshop presentations.
Review the descriptions of Panel discussions and Workshops.
Regina Hodits of Atlas Venture leads the Opening Panel discussion
BIO-Europe Spring’s plenary session, Collaboration in the Next Decade: Will 25 Years of Partnering Experience Lead to Greater Productivity? Regina Hodits, Partner at Atlas Venture, will moderate a panel featuring Ignacio Faus, CEO, Palau Pharma S.A.; Shelagh Wilson, VP, Head of European CEEDD, GlaxoSmithKline; and Isabelle Thizon De Gaulle, VP, R&D Scouting and Partnering, Sanofi-Aventis, to help answer the question.
“One of the biggest challenges over the next decade will be how the biotech and pharma industries adjust to their new roles either as commercial organizations or drug developers, with fewer doing both. It is clear by now that many of the old models for building fully integrated drug companies no longer work,” notes Hodits.
“The question is how do we capture and reward true innovation and progress along the drug development continuum so companies can specialize without being tempted to try to do it all. This will place a huge significance on partnerships,” she adds.
New this year is a featured Defined Health Therapeutic Insight Track that will offer a full afternoon dedicated to panels exploring transformative growth issues in leading therapeutic categories. Topics to be covered include:
- Getting to Proof of Relevance
- Shifting Cancer Care to Chemoprevention: Can We Ever Move to a Model of Treating Risk?
- Alzheimer’s Disease: Moving Forward, or Spinning Our Wheels?
- Antibiotics: A Revival of Fortunes?
Other panels delving into pertinent strategic issues include:
Can Mid-cap Companies Succeed with Targeted Regional Strategies?
Moderator Jeff Conroy, Adjuvant Global Advisors, and speakers Helmut Kessmann, Santhera Pharmaceuticals, Jukka Muhonen, Orion Corporation, and, Carlos de Sousa, Nycomed, examine strategies related to specific territories and disease areas that lend themselves to specialization, and smaller more nimble marketing and drug development operations.
Does Every Drug Idea Really Need a Company Behind it?
Moderator Jack M. Anthony, Osprey Pharmaceuticals USA, together with Anton Gueth, Burrill LLC, Wendy Johnson, Palkion, Inc., Dennis Purcell, Aisling Capital, and Robert Wills, Johnson & Johnson, will explore the myth that biotech will be the salvation of the drug industry by supplying novel drug opportunities. Can it possibly be that the biotech universe can no longer support every drug concept and the company behind it? How do we better match supply and demand? Or do we simply let Darwinian laws prevail? Don’t miss these five industry veterans, buy side and sell side, square off to try and bring clarity to a very fuzzy future.
Ben Bonifant, Campbell Alliance
Next Wave: Partnering and Financing Opportunities for Assets that Survived the Shake-out
Ben Bonifant, Campbell Alliance, moderates a panel featuring Christoph Hüls, Merck Serono and Tom Needham, Advent Healthcare Ventures, that seeks to identify the next wave of partnering and financing opportunities, ones that require a moderate level of investment, but could yield a disproportionate increase in value.
Corporate Venture in Drug Development: Is it Really Strategic or Merely Business Development Deal Sourcing by Another Name?
Moderator John Carroll, FierceBiotech, and Roel Bulthuis, Merck Serono Ventures, Anja König, Novartis Venture Fund, and Malcom Weir, Heptares Therapeutics, look into the effectiveness of corporate venture funds. Given the growing importance of corporate venture in financing early stage programs, this panel will answer key questions related to effectiveness of corporate venture arms in selecting early stage programs that could eventually be pulled in-house.
Related Posts
No related posts.